STOCK TITAN

Interpace Biosciences: $1.5M Q3 continuing operations loss

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Interpace Biosciences (IDXG) reported third-quarter 2026 revenue of $10.4 million, up 18% year over year, with thyroid test volume up 7%. Gross margin was 69%, compared with 62%, and Adjusted EBITDA was $2.1 million versus $1.3 million. Interpace also reported a $1.5 million loss from continuing operations, compared with $1.0 million income a year earlier; the loss included approximately $4.1 million in non-recurring stock compensation costs and non-recurring legal expenses.

For the nine months ended September 30, 2026, revenue was $28.5 million versus $29.5 million a year earlier; on the company’s thyroid-only Pro Forma basis, revenue rose 13% from $25.3 million. Net cash provided by operating activities was $1.351 million versus $3.693 million. Trailing 12-month thyroid revenue was $38.0 million, up approximately 13% on a comparable thyroid-only basis. The pancreatic cancer program remains in development, with analytical validation underway and clinical validation and utility studies planned across 2026 and 2027; Interpace does not expect it to contribute revenue in either year.

3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

How the balance works

Positive

  • Moderate pointQ3 revenue rose 18% year over year to $10.4 million.
  • Moderate pointQ3 gross margin rose to 69% from 62%.
  • Moderate pointAdjusted EBITDA increased to $2.1 million from $1.3 million.

Negative

  • Moderate pointContinuing-operations results shifted from $1.0 million income to a $1.5 million loss.
  • Moderate pointNine-month operating cash flow was $1.351 million, versus $3.693 million.

Filing Explained

At September 30, 2026, Interpace Biosciences reported $2,929 thousand in cash and cash equivalents and $6,438 thousand in current liabilities; cash was $2,505 thousand at December 31, 2025.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Q3 revenue $10.4 million Q3 2026; up 18% year over year from $8.8 million
Thyroid test volume 7% increase Q3 year over year
Gross margin 69% Q3 2026, compared with 62% in Q3 2025
Continuing-operations result $1.5 million loss Q3 2026, compared with $1.0 million income in Q3 2025
Adjusted EBITDA $2.1 million Q3 2026, versus $1.3 million in Q3 2025
Net cash provided by operating activities $1.351 million Nine months ended September 30, 2026, versus $3.693 million in the prior-year period
Trailing 12-month thyroid revenue $38.0 million Up approximately 13% over the comparable prior twelve-month period on a thyroid-only basis
Adjusted EBITDA financial
"Adjusted EBITDA was $2.1 million versus $1.3 million"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
Pro Forma financial
"the prior year period Pro Forma"
Pro forma refers to financial information that is prepared based on estimates or adjustments to show what a company's results might look like under certain scenarios, such as new projects or acquisitions. It helps investors understand the potential impact of future events by providing a clear, hypothetical view of financial performance, much like a weather forecast shows possible future conditions.
next-generation sequencing medical
"a next-generation sequencing assay"
Next-generation sequencing is a set of laboratory techniques that read large amounts of DNA or RNA quickly and cheaply by processing millions of short genetic fragments in parallel, rather than one at a time. For investors, it matters because faster, lower-cost genetic data powers drug discovery, diagnostic tests and personalized medicine, creating scalable revenue opportunities and competitive advantages for companies that own the technology or services.
microRNA pairwise expression profiler medical
"a proprietary microRNA pairwise expression profiler"
analytical validation technical
"Analytical validation of the panel design is underway"
Analytical validation is the process of proving a laboratory test or measurement consistently and accurately measures what it is supposed to measure — for example confirming a blood test detects a specific molecule at the right levels and gives the same result each time. For investors it matters because strong analytical validation reduces regulatory and commercial risk: it supports product approvals, builds customer trust, and lowers the chance of costly recalls or repeat testing, much like calibration ensures a scale gives correct weights every time.
neoadjuvant treatment selection medical
"pancreatic cancer detection, classification, and neoadjuvant treatment selection"
Revenue $10.4 million Up 18% year over year from $8.8 million
Gross margin 69% Compared with 62% in Q3 2025
Loss from continuing operations $1.5 million loss Compared with $1.0 million income in Q3 2025
Adjusted EBITDA $2.1 million Versus $1.3 million in Q3 2025
Guidance

Interpace does not expect the pancreatic cancer program to contribute revenue in 2026 or 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did IDXG report in Q3 2026?

IDXG reported Q3 2026 revenue of $10.4 million, up 18% year over year from $8.8 million. Thyroid test volume increased 7% year over year, and thyroid revenue increased 18%.

Did IDXG make a profit in Q3 2026?

Interpace reported a $1.5 million loss from continuing operations, compared with $1.0 million income in Q3 2025. It said the current-quarter loss included approximately $4.1 million of non-recurring stock compensation costs and non-recurring legal expenses.

What is the status of IDXG's pancreatic cancer program?

The pancreatic cancer program is in development, and analytical validation of the panel design is underway. Clinical validation and utility studies are planned across 2026 and 2027, followed by planned reimbursement and launch activities. The product is not available for clinical use, and Interpace does not expect the program to contribute revenue in 2026 or 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001054102 0001054102 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 16, 2026

 

INTERPACE BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   0-24249   22-2919486
(State or other jurisdiction
of incorporation)
 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

Waterview Plaza, Suite 310, 2001 Route 46

Parsippany, NJ 07054

(Address, including zip code, of principal executive offices)

 

(855) 776-6419

Registrant’s telephone number, including area code

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 16, 2026, Interpace Biosciences, Inc. issued a press release announcing its results of operations and financial condition for the quarter ended September 30, 2026. The full text of the press release is set forth as Exhibit 99.1 attached hereto and is incorporated herein by reference.

 

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number   Description
99.1   Press Release, dated November 16, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INTERPACE BIOSCIENCES, INC.
     
  By: /s/ Thomas W. Burnell
  Name: Thomas W. Burnell
  Title: President and Chief Executive Officer

 

Date: November 17, 2026

 

 

 

 

Exhibit 99.1

 

 

Interpace Biosciences Announces Third Quarter 2026 Financial and Business Results

 

●Q3 Revenue of $10.4 million
●Q3 Thyroid volume year-over-year increase of 7%
●Q3 Thyroid revenue year-over-year increase of 18%
●Trailing twelve-month thyroid revenue of $38.0 million, an increase of 13% on a comparable thyroid-only basis

 

PARSIPPANY, NJ, November 16, 2026 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCID: IDXG) today announced financial results for the third quarter ended September 30, 2026 and provided a business and financial update.

 

Interpace generated Q3 2026 revenue of $10.4 million, up 18% year-over-year, a loss from continuing operations of $1.5 million compared to income from continuing operations of $1.0 million in the prior year, and produced Adjusted EBITDA of $2.1 million, or 20% of revenue. The loss from continuing operations of $1.5 million included approximately $4.1 million of non-recurring stock compensation costs and non-recurring legal expenses.

 

As previously disclosed, the Company discontinued its PancraGEN® pancreatic testing business in May 2025 and now operates as a thyroid-only molecular diagnostics company. Prior-year reported results therefore include PancraGEN revenue and related costs, while the Company’s current-year results do not. Reported year-over-year comparisons for the nine-month period are affected by this change, and the Pro Forma prior-year results presented below exclude PancraGEN in order to show the underlying thyroid business on a consistent basis. Beginning with the third quarter of 2026, reported year-over-year comparisons will be presented on a directly comparable thyroid-only basis, as the prior-year comparative periods no longer include PancraGEN.

 

“The Company continued to convert revenue growth into margin expansion in the third quarter, reflecting the operating leverage we have built into the business,” said Chris McCarthy, Chief Financial Officer. “Gross margin expanded to 69% in Q3 2026, up from 62% in Q3 2025 and 63% on a Pro Forma basis, supported by an 11% increase in average thyroid revenue per test and continued efficiency gains in our laboratory. That gross margin expansion carried through to the bottom line: Adjusted EBITDA margin improved to 20% from 14% in the prior year quarter and 17% on a Pro Forma basis, with Adjusted EBITDA increasing to $2.1 million from $1.3 million. Year-to-date, gross margin has expanded to 66% from 59%, and Adjusted EBITDA margin to 15% from 10%, compared to the prior year period on a Pro Forma basis. Q3 2026 revenue grew 18% to $10.4 million, or 15% on a Pro Forma basis, on 7% growth in thyroid test volume. These results reflect steady execution across our commercial and operations teams, and the clinical value physicians continue to see in ThyGeNEXT® and ThyraMIR®v2.”

 

McCarthy added, “Our debt-free balance sheet continues to support meaningful investment in laboratory automation, AI-enabled productivity initiatives across our workflow, and research and development to advance our pipeline. Those investments are already showing up in our laboratory, where average ThyGeNEXT® and ThyraMIR®v2 turnaround time improved approximately 11% in the first nine months of 2026 compared to the prior year period. We are scaling operating leverage in line with volume growth without a corresponding increase in headcount, which we expect will support continued margin expansion.”

 

 

 

 

“The third quarter demonstrates the durability of the business we built through last year’s transition and the operating discipline we will carry through the remainder of 2026 and into 2027,” said Tom Burnell, President and CEO. “We see the same characteristics in Q3 2026 that defined our 2025 performance — disciplined execution, expanding clinical adoption, and a steady cadence of operational improvement. We continue to believe our combination approach — ThyGeNEXT® for mutation detection and ThyraMIR®v2 for microRNA pathway insights — gives physicians the confidence and clarity they need to make informed patient-management decisions.”

 

All share and per share numbers in this release give effect to the one-for-five reverse stock split effected on August 27, 2026.

 

Pancreatic Cancer Program Update

 

Interpace is seeking to extend the next-generation sequencing and microRNA technology platforms behind ThyGeNEXT® and ThyraMIR®v2 into pancreatic cancer. The program design includes an extensive genomic panel and proprietary microRNA classification aligned with National Comprehensive Cancer Network (NCCN) guidelines. Together, these technologies are intended to provide decision-making support to clinicians, including medical oncologists, for pancreatic cancer detection, classification, and neoadjuvant treatment selection. Analytical validation of the panel design is underway, with clinical validation and utility studies planned across 2026 and 2027, and reimbursement and launch activities to follow. This new product is in development, not yet available for clinical use, and has not been cleared or approved by the U.S. Food and Drug Administration. There can be no assurance that development will be completed on the anticipated timeline or at all, and the Company does not expect the program to contribute revenue in 2026 or 2027.

 

Third Quarter 2026 Financial Performance

 

For the Third Quarter of 2026 as Compared to the Third Quarter of 2025:

 

●Revenue was $10.4 million, an increase of 18% from $8.8 million for the prior year quarter.
●Gross Profit percentage was 69% compared to 62% for the prior year quarter.
●Operating loss was $2.4 million versus operating income of $1.1 million in the prior year quarter.
●Loss from continuing operations was $1.5 million versus income from continuing operations of $1.0 million in the prior year quarter.
●Loss from continuing operations for the third quarter of 2026 included approximately $4.1 million of non-recurring stock compensation costs and non-recurring legal expenses. These charges are excluded from Adjusted EBITDA.
●Adjusted EBITDA was $2.1 million versus $1.3 million in the prior year quarter.
●Adjusted EBITDA margin was approximately 20% compared to approximately 14% for the prior year quarter.
●Q3 2026 cash collections totaled $9.1 million compared to $10.0 million in the prior year quarter.

 

Year-to-Date and Trailing Twelve-Month Performance

 

●Revenue for the nine months ended September 30, 2026 was $28.5 million, a decrease from $29.5 million for the prior year period and an increase of 13% from $25.3 million for the prior year period Pro Forma.
●Gross Profit percentage for the nine months ended September 30, 2026 was 66% compared to 61% for the prior year period and 59% for the prior year period Pro Forma.
●Loss from continuing operations for the nine months ended September 30, 2026 was $0.4 million compared to income from continuing operations of $2.2 million for the prior year period and $1.0 million for the prior year period Pro Forma, and included approximately $4.4 million of non-recurring stock compensation costs and non-recurring legal expenses.

 

 

 

 

●Adjusted EBITDA for the nine months ended September 30, 2026 was $4.4 million, or 15% of revenue, compared to $3.7 million, or 13% of revenue for the prior year period and $2.5 million, or 10% of revenue, for the prior year period Pro Forma.
●On a trailing twelve-month basis, thyroid revenue was $38.0 million, an increase of approximately 13% over the comparable prior twelve-month period Pro Forma, on trailing twelve-month thyroid test volume growth of approximately 9%.

 

Management uses a non-GAAP Pro Forma income statement to help evaluate the results of our performance. The Pro Forma income statement for 2025 reflects the Company’s current business structure as a thyroid-only diagnostics testing company and excludes revenue and related costs from PancraGEN, which was discontinued in May 2025. These adjustments are presented for comparability purposes only and do not represent GAAP financial measures. Investors should review GAAP results alongside these pro forma figures for a complete understanding of performance. A reconciliation of GAAP and these pro forma figures is presented below.

 

About Interpace Biosciences

 

Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

 

Clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests and bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has two commercialized molecular tests: ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next-generation sequencing assay and ThyraMIR®v2, used in combination with ThyGeNEXT®, for the diagnosis of thyroid cancer utilizing a proprietary microRNA pairwise expression profiler along with algorithmic classification.

 

For more information, please visit Interpace Biosciences’ website at www.interpace.com.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company’s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statements, including, but not limited to, the possibility that the Company’s estimates of future revenue, cash flows, and net income, as well as Pro Forma financial results and adjusted EBITDA may prove to be materially inaccurate, the Company’s prior history of operating losses, the Company’s ability to adequately finance its business and seek alternative sources of financing, the Company’s dependence on sales and reimbursements from its clinical services, the Company’s ability to retain or secure reimbursement including its reliance on third parties to process and transmit claims to payers and the adverse impact of any delay, data loss, or other disruption in processing or transmitting such claims, and the Company’s revenue recognition being based in part on estimates for future collections which estimates may prove to be incorrect.

 

Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

 

Contacts

 

Investor Relations

Interpace Biosciences, Inc.

(855)-776-6419

Info@Interpace.com

 

 

 

 

INTERPACE BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2026   2025   2026   2025 
   (unaudited)   (unaudited) 
                 
Revenue, net  $10,373   $8,756   $28,537   $29,504 
Cost of revenue   3,193    3,317    9,799    11,418 
Gross Profit   7,180    5,439    18,738    18,086 
                     
Sales and marketing   2,704    2,087    7,088    7,811 
Research and development   160    150    461    500 
General and administrative   6,716    2,057    12,143    7,268 
Total operating expenses   9,580    4,294    19,692    15,579 
                     
Operating (loss) income   (2,400)   1,145    (954)   2,507 
Note payable interest expense   -    (30)   -    (156)
Other income (expense), net   15    (115)   33    (112)
(Loss) income from continuing operations before tax   (2,385)   1,000    (921)   2,239 
Benefit (provision) for income taxes   (884)   (11)   (517)   7 
(Loss) income from continuing operations   (1,501)   1,011    (404)   2,232 
                     
Loss from discontinued operations, net of tax   (109)   (100)   (327)   (314)
                     
Net (loss) income  $(1,610)  $911    (731)   1,918 
                     
Basic income (loss) per share of common stock:                    
From continuing operations  $(0.26)  $1.14   $(0.08)  $2.52 
From discontinued operations   (0.02)   (0.11)   (0.06)   (0.35)
Net income (loss) per basic share of common stock  $(0.28)  $1.03   $(0.14)  $2.17 
                     
Diluted income (loss) per share of common stock:                    
From continuing operations  $(0.26)  $0.18   $(0.08)  $0.40 
From discontinued operations   (0.02)   (0.02)   (0.06)   (0.06)
Net income (loss) per diluted share of common stock  $(0.28)  $0.16   $(0.14)  $0.35 
                     
Weighted average number of common shares and common share equivalents outstanding:                    
Basic   5,705    885    5,210    885 
Diluted   5,705    5,539    5,210    5,539 

 

 

 

 

Selected Balance Sheet Data

($ in thousands)

 

   September 30,   December 31, 
   2026   2025 
         
Cash and cash equivalents  $2,929   $2,505 
           
Total current assets   13,286    9,900 
Total current liabilities   6,438    5,103 
           
Total assets   37,468    33,838 
Total liabilities   12,777    11,475 
Total stockholders’ equity   24,691    22,363 

 

 

 

 

Selected Cash Flow Data

($ in thousands)

 

   For the Nine Months Ended 
   September 30, 
   2026   2025 
         
Net (loss) income  $(731)  $1,918 
           
Net cash provided by operating activities  $1,351   $3,693 
Net cash used in investing activities   (567)   (318)
Net cash used in financing activities   (360)   (3,413)
Change in cash and cash equivalents   424    (38)
Cash and cash equivalents – beginning   2,505    1,461 
Cash and cash equivalents – ending  $2,929   $1,423 

 

 

 

 

Reconciliation of Pro Forma (Unaudited)

(in thousands, except per share data)

 

   Nine Months Ended September 30, 2025 
       PancraGEN     
   As Reported   Direct Costs*   Pro Forma 
             
Revenue, net  $29,504   $4,193   $25,311 
Cost of revenue   11,418    1,023    10,395 
Gross Profit   18,086    3,170    14,916 
                
Sales and marketing   7,811    1,653    6,158 
Research and development   500    100    400 
General and administrative   7,268    193    7,075 
Total operating expenses   15,579    1,946    13,633 
                
Operating income   2,507    1,224    1,283 
                
Note payable interest   (156)   -    (156)
Other expense, net   (112)   -    (112)
Income from continuing operations before tax   2,239    1,224    1,015 
Provision for income taxes   7    -    7 
Income from continuing operations   2,232    1,224    1,008 
                
Loss from discontinued operations, net of tax   (314)   -    (314)
                
Net income  $1,918   $1,224   $694 
                
Basic income (loss) per share of common stock:               
From continuing operations  $2.52   $1.38   $1.14 
From discontinued operations   (0.35)   -    (0.35)
Net income (loss) per basic share of common stock  $2.17   $1.38   $0.78 
                
Diluted income (loss) per share of common stock:               
From continuing operations  $0.40   $0.22   $0.18 
From discontinued operations   (0.06)   -    (0.06)
Net income (loss) per diluted share of common stock  $0.35   $0.22   $0.13 
                
Weighted average number of common shares and common share equivalents outstanding:               
Basic   885    885    885 
Diluted   5,539    5,539    5,539 

 

* PancraGEN Direct Costs represent only direct costs associated with the operations of PancraGEN testing, with no allocations or estimates of corporate, shared, or overhead expenses included.

 

 

 

 

Reconciliation of Adjusted EBITDA (Unaudited)

($ in thousands)

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2026   2025   2026   2025 
(Loss) income from continuing operations (GAAP Basis)  $(1,501)  $1,011   $(404)  $2,232 
Depreciation and amortization   141    111    386    307 
Stock-based compensation   3,993    7    4,001    31 
Non-recurring legal expenses   234    -    614    - 
Severance & related expense   -    -    -    692 
Asset impairment - lab supplies   -    -    -    198 
Loss on sale of asset   104    -    104    - 
Lab supplies write-off   -    -    217    - 
Income tax (benefit) expense   (884)   (11)   (517)   7 
Note payable interest   -    30    -    156 
Other income/expense, net   (15)   10    (33)   25 
Change in fair value of note payable   -    105    -    87 
Adjusted EBITDA  $2,072   $1,263   $4,368   $3,735 

 

Non-GAAP Financial Measures

 

In addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, we have provided certain non-GAAP financial measures to help evaluate the results of our performance. We believe that these non-GAAP financial measures, when presented in conjunction with comparable GAAP financial measures, are useful to both management and investors in analyzing our ongoing business and operating performance. We believe that providing the non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view our financial results in the way that management views financial results.

 

In this document, we discuss Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is a metric used by management to measure cash flow of the ongoing business. Adjusted EBITDA is defined as income or loss from continuing operations, plus depreciation and amortization, non-cash stock-based compensation, severance expense, asset impairment-lab supplies, non-recurring legal expenses, interest and taxes, and other non-cash expenses including change in fair values of notes payable. The table above includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure.

 

 

 

Filing Exhibits & Attachments

5 documents

Keep reading